MET and non-small cell lung carcinoma: Due to the inevitable development of resistance in non-small cell lung cancer (NSCLC) with TKI treatment, the high frequency of activation of the Hh pathway and c-MET signaling initially drew attention to the dual inhibition of c-MET and SMO.